AS the KanaVape case awaits European Court of Justice (ECJ) ratification its implications for the hemp and CBD markets across the continent are still uncertain, says Tim Phillips, Managing Director of Barcelona-based CBD-Intel.
“This is a really complex area of law, and while I do think that this is of course a positive step for hemp-derived CBD in Europe, we should perhaps not jump too far along the track of celebrating the removal of restrictions over using hemp flower in general within the EU.
The rules on manufacturing and/or selling CBD product extracted from flower is a real patchwork across the EU, and difficult to summarise in a paragraph.
Suffice to say that even though the black and white law might be a patchwork, and important cases like the KanaVape case will help to clarify and solidify this legal landscape, the reality on the ground is that the law is poorly enforced across the EU and manufacturing from flower and selling products derived from flower is certainly very widespread, as it has to be due to the manufacturing process.
Law-Abiding Business Suffer
The problem with overly burdensome laws like we have seen as the subject of the KanaVape case is that very law-abiding companies will try hard to stick to the rules, but the market becomes dominated by companies who are willing to take a risk.
The idea that hemp flower should be left to rot and CBD be manufactured from the left-over stems and seeds is just not practicable or economic, so this sort of restriction does not sit comfortably alongside regulations which allow the sale of CBD finished products on the market.
There is also the added difficulty of enforcement for authorities – given the difficulty in identifying and distinguishing hemp flower from ‘marijuana’ (cannabis flowers).
However, the EU Advocate General’s opinion needs to be followed by the court, which is not a given, particularly in a very controversial sector such as this.
The extent to which it sets a precedent for courts in other European markets will depend on how narrowly the case is interpreted – whether it just affects the legality of importation of CBD products derived from flower extraction in EU countries where it is allowed to be extracted in this way, or whether it can be interpreted more widely to enable extraction from flower in all EU markets?
Novel Food & Other Regulatory Issues
It is worth remembering that other restrictions may be implemented in place of the ban which is the subject of the court case.
In addition, there are many other regulatory issues which will also impact the CBD market over the next few months and years, including Novel Food regulations for CBD ingestible products, and a re-negotiation of the Tobacco Products Directive which we expect to include CBD in vape products.
Nevertheless, the more regulators start to understand the CBD market and the reality about the manufacturing process for the product, the more likely we are to get sensible regulations which encourage law abiding compliant companies to enter the market, and compete successfully against those companies who ignore the rules.”
Tim Phillips, Managing Director, CBD-Intel
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide.
The Potential Impacts Of The Controversial KanaVape Case Examined By Tim Phillips Of CBD-Intel
AS the KanaVape case awaits European Court of Justice (ECJ) ratification its implications for the hemp and CBD markets across the continent are still uncertain, says Tim Phillips, Managing Director of Barcelona-based CBD-Intel.
“This is a really complex area of law, and while I do think that this is of course a positive step for hemp-derived CBD in Europe, we should perhaps not jump too far along the track of celebrating the removal of restrictions over using hemp flower in general within the EU.
The rules on manufacturing and/or selling CBD product extracted from flower is a real patchwork across the EU, and difficult to summarise in a paragraph.
Suffice to say that even though the black and white law might be a patchwork, and important cases like the KanaVape case will help to clarify and solidify this legal landscape, the reality on the ground is that the law is poorly enforced across the EU and manufacturing from flower and selling products derived from flower is certainly very widespread, as it has to be due to the manufacturing process.
Law-Abiding Business Suffer
The problem with overly burdensome laws like we have seen as the subject of the KanaVape case is that very law-abiding companies will try hard to stick to the rules, but the market becomes dominated by companies who are willing to take a risk.
The idea that hemp flower should be left to rot and CBD be manufactured from the left-over stems and seeds is just not practicable or economic, so this sort of restriction does not sit comfortably alongside regulations which allow the sale of CBD finished products on the market.
There is also the added difficulty of enforcement for authorities – given the difficulty in identifying and distinguishing hemp flower from ‘marijuana’ (cannabis flowers).
However, the EU Advocate General’s opinion needs to be followed by the court, which is not a given, particularly in a very controversial sector such as this.
The extent to which it sets a precedent for courts in other European markets will depend on how narrowly the case is interpreted – whether it just affects the legality of importation of CBD products derived from flower extraction in EU countries where it is allowed to be extracted in this way, or whether it can be interpreted more widely to enable extraction from flower in all EU markets?
Novel Food & Other Regulatory Issues
It is worth remembering that other restrictions may be implemented in place of the ban which is the subject of the court case.
In addition, there are many other regulatory issues which will also impact the CBD market over the next few months and years, including Novel Food regulations for CBD ingestible products, and a re-negotiation of the Tobacco Products Directive which we expect to include CBD in vape products.
Nevertheless, the more regulators start to understand the CBD market and the reality about the manufacturing process for the product, the more likely we are to get sensible regulations which encourage law abiding compliant companies to enter the market, and compete successfully against those companies who ignore the rules.”
Tim Phillips, Managing Director, CBD-Intel
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide.
www.cbd-intel.com
Tens Of Thousands Could Benefit From Stop-Gap To Address UK Medical Cannabis Impasse
Next PostKatie Pringle, Marigold Marketing + PR and Womxn, Wellness Cannabis Conference
Peter
Related Posts
Related Posts
UK’s Medical Cannabis Boom: Patients, Demand, and Consumption Surge to All-Time Highs – With a Record Number of Private Clinics
The UK is the primary driver of new growth in Europe’s medical cannabis market, with sales of medical cannabis greater...
SynBiotic Acquires German Wholesaler Weeco as Clever Leaves & OCT Reveal Plans to Delist as Stocks Struggle
Synbiotic German cannabis group SynBiotic has capitalised on the recent explosion in medical cannabis patients since the country’s landmark...
Speedy Amnesty for Cannabis Convictions in Germany
Progress for UK CBD Industry: FSA Issues First Positive Safety Assessments in Novel Food Process
Unlocking the Potential: UK’s Evolving Landscape of Medical Cannabis Research
European Cannabis Leaders to Take Center Stage at Business of Cannabis Awards 2024
CONNECT
Related Posts
Related Posts
UK’s Medical Cannabis Boom: Patients, Demand, and Consumption Surge to All-Time Highs – With a Record Number of Private Clinics
The UK is the primary driver of new growth in Europe’s medical cannabis market, with sales of medical cannabis greater...
SynBiotic Acquires German Wholesaler Weeco as Clever Leaves & OCT Reveal Plans to Delist as Stocks Struggle
Synbiotic German cannabis group SynBiotic has capitalised on the recent explosion in medical cannabis patients since the country’s landmark...
Speedy Amnesty for Cannabis Convictions in Germany
Written for Business of Cannabis by Prohibition Partners Senior Analyst Alex Khourdaji According to a recent request made by...
Progress for UK CBD Industry: FSA Issues First Positive Safety Assessments in Novel Food Process
The UK’s Food Standards Agency (FSA) has issued the first two ‘positive safety assessments’ for CBD (cannabidiol) products as part...
Unlocking the Potential: UK’s Evolving Landscape of Medical Cannabis Research
Written for Business of Cannabis by Releaf. The UK moved to legalise medical cannabis in 2018, but while the market...
Recent Posts
Related Posts
Ireland’s Prohibitionist Approach To Hemp And CBD Exposes It To Punitive Sanctions From The EU
A HIGH Court decision to ignore the ground-breaking KanaVape case could expose the Irish Government to financial penalties and the...
German Prohibitionists Lobby EU, German Medical Cannabis Re-Think, High Court Blow For Irish CBD, Hemp Batteries In Electric Vehicles?
GERMAN opponents of its adult-use cannabis programme are taking their fight to Brussels in a bid to scupper the plans....
German Courts Continue To Prosecute Hundreds Of Cannabis Businesses Despite Looming Legalisation
HUNDREDS of companies are still being hounded through the German courts for alleged breaches of the country’s strict cannabis laws...
European Commission Validates Five Natural Plant CBD Novel Food Applications In Milestone For Industry
FEARS the European Commission will once more change its position on the status of CBD have receded after it Validated...
Good News For CBD Industry After France’s Highest Court Suspends Government Ban On Flowers
THE French CBD industry is celebrating after Government efforts to outlaw the sale of CBD flowers were suspended by the...
Subscribe to our mailing list to receives daily updates!
We won’t spam you
Categories
Browse by Tags